Neuromyelitis optica
Conditions
Interventions
Plasma exchange (PE group): Will be performed 4 times within 14 days after the efficacy of the steroid pulse therapy has been evaluated, for each session, the final volume of treated plasma is 30mL/kg
Sponsors
Saitama Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with optic neuritis or myelitis who either initially presented with NMO or NMO spectrum disorders suspected to be positive for the anti-AQP4 antibody titer or tested positive for the anti-AQP4 antibody titer, and who have been diagnosed with relapsing NMO or NMO spectrum disorders in a period of acute exacerbation
Exclusion criteria
Exclusion criteria: Patients considered to be due to brain lesions, the only local symptoms and disturbance of consciousness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in QOSI score on day 7 after the first course of blood purification therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Anti-AQP4 antibody titer during evaluation period Initial effect Steroid pulse therapy efficacy rate Crossover study implementation rate Crossover study efficacy Adverse events | — |
Countries
Japan
Contacts
Public ContactKyoichi Nomura
Saitama Medical Center Department of Neurology
Outcome results
None listed